HighTower Advisors’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

HighTower Advisors’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,158	Closed	-$25K	–	3715
2022 Q4	$25K	Sell	2,158 -640	-23%	-$11.3K	﹤0.01%	3112
2022 Q3	$58K	Hold	2,798	–	–	﹤0.01%	2861
2022 Q2	$65K	Hold	2,798	–	–	﹤0.01%	2870
2022 Q1	$139K	Sell	2,798 -26	-0.9%	-$1.28K	﹤0.01%	2920
2021 Q4	$196K	Buy	2,824 +1,284	+83%	+$108K	﹤0.01%	2788
2021 Q3	$143K	Buy	1,540 +7	+0.5%	+$665	﹤0.01%	2794
2021 Q2	$156K	Buy	1,533 +161	+12%	+$15.7K	﹤0.01%	2721
2021 Q1	$127K	Buy	+1,372	New	+$139K	﹤0.01%	2715
2020 Q4	–	Sell	-1,396	Closed	-$119K	–	2988
2020 Q3	$119K	Sell	1,396 -355	-20%	-$41.4K	﹤0.01%	2207
2020 Q2	$164K	Buy	1,751 +1,366	+355%	+$75.3K	﹤0.01%	2038
2020 Q1	$11K	Sell	385 -42	-10%	-$1.63K	﹤0.01%	2116
2019 Q4	$17K	Buy	427 +50	+13%	+$1.09K	﹤0.01%	2178
2019 Q3	$5K	Buy	+377	New	+$7.89K	﹤0.01%	2341

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HighTower Advisors's VBIV Position: Q1 2023 in Review

HighTower Advisors sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q1 2023, closing a stake of 2,158 shares — an estimated $25K sold.

HighTower Advisors first reported a position in VBIV in Q3 2019 and held it in 13 quarters. The position peaked at $196K in Q4 2021. 95 funds tracked by Wall St. Rank hold VBIV as of Q1 2023.

HighTower Advisors reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q1 2023 after selling out during the quarter.
HighTower Advisors sold 2,158 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q1 2023, an estimated $25K.
HighTower Advisors first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2019 and held it in 13 quarters.
HighTower Advisors's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $196K in Q4 2021.
95 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.